RecentRCT

OBERON / TITANIA

Tozorakimab to Prevent COPD Exacerbations.

The New England journal of medicine, 2026 · Two replicate placebo-controlled phase 3 trials

Population: 877 and 873 current/former smokers with recurrent COPD exacerbations despite maintenance inhalers
Intervention: Tozorakimab 300 mg subcutaneously every four weeks for 52 weeks
Comparator: Placebo
Primary outcome: Annualized moderate/severe exacerbation rate among former smokers
Result: Former-smoker rate ratios 0.71 (95% CI 0.57–0.88) and 0.66 (0.55–0.80); overall-population rates also favored treatment.

What the trial found

Former-smoker rate ratios 0.71 (95% CI 0.57–0.88) and 0.66 (0.55–0.80); overall-population rates also favored treatment.

Clinical interpretation

Evidence concerns maintenance prevention, not rescue treatment during an exacerbation. Consider evolving regulatory/local guidance and specialist selection before clinical adoption.

Limitations

Industry-funded; one-year prevention studies, not ICU rescue trials.
No acute-exacerbation benefit or mortality effect should be inferred from the annualized-rate endpoint.

Moderate certainty

Clinical Context & Relevant Topics (1)

Disease Reference

COPD Exacerbation (Acute & Severe)

Pathophysiology of acute-on-chronic hypercapnia, controlled oxygen targets (88–92%), evidence-based NIV, and auto-PEEP matching mechanics.

View Topic Context →